Abstract. Kv1.5 is considered to be a potential molecular target for treatment of atrial fibrillation or flutter. Disopyramide is widely used in the treatment of atrial flutter and / or atrial fibrillation. The present study was undertaken to characterize the effects of disopyramide on currents mediated by Kv1.5 channels and to determine the putative binding site involved in the inhibitory effects of disopyramide. Experiments were carried out on wild-type and site directed mutated hKv1.5 channels expressed on HEK 293 cells using the patch-clamp technique. Disopyramide acting from the cytoplasmic side of the membrane produced blocking effects on Kv1.5 that exhibited several features typical of an open channel blocker. Ala-scanning mutagenesis of the Kv1.5 pore domain combined with macroscopic current analysis suggested that disopyramide interacted only with the Val512 residue that faces to the central cavity of the channel. Mutation of this key residue to Ala caused marked change in the IC 50 of disopyramide (22-fold). The single interaction between disopyramide and Val512 in the PVP region is able to change the mechanism of channel closure, reproducing the "foot-in-the-door" phenomenon.
Introduction
The most common sustained cardiac arrhythmias in clinical practice are atrial flutter and / or atrial fibrillation (AF). The goals of antiarrhythmic therapy are to restore sinus rhythm, to facilitate electrical cardioversion, to prevent AF recurrence, and to control ventricular rate (1) . Kv1.5 channels are highly expressed in human atria (but not ventricle) and conduct the ultrarapid delayed rectifier current (I Kur ) that contributes to action potential repolarization of human atrial myocytes (2 -4) . Thus, Kv1.5 is a potential target for treatment of atrial fibrillation or atrial flutter. In different animal models, it was shown that AF could be terminated effectively by selective blockers of I Kur (5, 6) . Also in human atria, selective block of I Kur produced a stronger prolongation of action potential in patients with AF compared to patients with sinus rhythm (SR) (7) . Class 1A (sodium channel blocker) and Class III (potassium channel blocker) antiarrhythmic agents reduce the rate of recurrence of AF, but are of limited use because of a variety of potentially adverse effects including ventricular proarrhythmia (1, 8) . Disopyramide is a widely used Class Ia antiarrhythmic agent that is employed in the treatment of AF (9) . Disopyramide is a nonspecific channel blocker (9) , which blocks cardiac Na + channels to slow conduction (10 -12) . In addition, disopyramide blocks repolarizing cardiac K + channels to prolong action potential duration (13 -16) .
Ongoing studies of potassium channel inhibition by synthetic compounds and toxins provide important contributions to our understanding of these membrane proteins. Classical ion channel blockers, such as local anesthetics and antiarrhythmics are used both clinically and as molecular probes for studying ion channel function. Drug-binding from the internal side takes place inside a large water-filled inner cavity and requires a change in protein conformation to allow entrance of the blocker. Disopyramide blocks various potassium currents like the transient outward current I to (15) and the delayed rectifying outward current I Kr (13, 14, 16) . Disopyramide is suggested to bind only to open channels and either has extremely low affinity or is unable to bind to closed channels (15 -17) . To our knowledge, the effect of disopyramide on I Kur or Kv1.5 has not been studied.
Identification of the drug binding site and understanding of the channel blocker binding mode may help to promote the development of in silico prediction methods for identifying potential Kv1.5 channel blockers. Quinidine has been reported to block Kv1.5 by interacting primarily with residues in the S6 domain (18) . Recently, Decher et al. (19, 20) used an alaninescanning mutagenesis approach to define residues in the pore of Kv1.5 that interact with S0100176 and AVE0118, two novel antiarrhythmic agents. Mutation of residues located at the base of the pore helix and the S6 domain had the greatest effect on reducing the potency of these Kv1.5 channel blockers. In the present study, we investigated the effects of disopyramide on currents mediated by Kv1.5 channels expressed in a mammalian cell line, with the following aims: i) to characterize the nature of the inhibitory action on Kv1.5 by disopyramide; and ii) to define the molecular basis of disopyramide block of Kv1.5 channels.
Materials and Methods

Molecular biology
Wild-type (WT) and mutant Kv1.5 (KCNA5) cDNA were generously donated by Dr. Michael Sanguinetti from the University of Utah and Dr. Niels Decher (Aventis Pharma GmbH, Frankfurt, Germany).
Transfection of HEK 293 cells
HEK 293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% horse serum at 37°C in an air 5% CO 2 incubator. Cells were transiently transfected using Lipofectamine 2000 (Invitrogen, Mexico City, Mexico) according to the supplier's directions. Soluble GFP was coexpressed with the channel subunits to identify cells for voltage clamp experiments.
Voltage clamp protocols
Currents were recorded at room temperature (23°C -25°C) with standard patch clamp techniques. The external solution contained 130 mM NaCl, 4 mM KCl, 1 mM MgCl 2 , 10 mM Hepes, 1.8 mM CaCl 2 , and 10 mM glucose (pH was adjusted to 7.35 with NaOH). Patch pipettes were filled with 5 mM K 4 BAPTA, 100 mM KCl, 10 mM Hepes, 5 mM MgCl 2 , 5 mM ATP-K 2 (pH adjusted to 7.2 with KOH). The holding potential was −80 mV. The interpulse interval for all the protocols was 15 s to allow channels to fully recover from inactivation between pulses. To obtain current-voltage relationships and activation curves, 200-ms voltage steps were applied in 10-mV increments to potentials that varied from −60 to +60 mV, followed by repolarization to −40 mV. The ratio of current in the presence of drug divided by current before drug (I drug /I control ) was determined to calculate the fraction of unblocked current as a function of time. The time constant of current block ( b ) was determined by fitting I drug /I control to a monoexponential function. The voltage dependence of Kv1.5 channel activation (with or without disopyramide) was determined from tail current analyses at −40 mV. The resulting relationship between test voltage (V t ) and normalized tail current (In) was fit to a Boltzmann equation to obtain the halfpoint (V 1/ 2 ) and slope factor (k): 
Data analyses
pCLAMP 8 (Molecular Devices, Sunnyvale, CA, USA) and Origin 7 (OriginLab Corp, Northampton, MA, USA) software were used for data acquisition and analysis on a personal computer. All the fitting procedures were based on the simplex algorithm. The concentration required for 50% block of current (IC 50 ) was determined from Hill plots using 3 -5 concentrations of drug for each mutant (5 -12 cells / point). Results are each reported as the mean ± S.E.M. (n = number of cells). Statistical differences between WT and mutant channels were evaluated by ANOVA and Bonferroni's test. Significance was assumed for P<0.05.
Drugs
Disopyramide (Sigma-Aldrich, Mexico City, Mexico) was prepared daily, dissolved at the desired concentrations in the external or internal solution.
Results
Voltage-dependent block of Kv1.5 channels by disopyramide
The effect of disopyramide on Kv1.5 was characterized by recording currents in a voltage range from −60 to +60 mV, applied in 10-mV increments from a holding potential of −80 mV. In the absence of drug, Kv1.5 slowly inactivates during the test pulse (Fig. 1A) . In the presence of drug, the current appeared to inactivate much faster and more thoroughly, but this effect more likely represents open channel block (Fig. 1B) . Disopyramide caused a voltage-dependent decrease in Kv1.5 currents elicited by depolarizations between −10 and +10 mV. For depolarizations greater than +10 mV, current reduction was no longer voltage-dependent ( Fig. 1: C and D) . The lack of an increase in block at higher potentials suggests that this compound does not preferentially block Kv1.5 channels in the inactivated state. Disopyramide caused a slight hyperpolarizing shift in the voltage dependence of activation (V 1/ 2 −8.0 ± 0.5 mV before and −13.9 ± 0.8 mV after 100 μM disopyramide, Fig. 1E ). Figure 1F shows the superposition of the tail currents obtained at −40 mV after a 200-ms depolarization to +60 mV under control conditions and in the presence of 100 μM disopyramide. In control, the tail declined with a time constant of 27.1 ± 5.1 ms. After exposure to disopyramide, the decline of the tail current was slower than in the control with a time constant of 60.1 ± 8.7 ms, resulting in the "crossover" phenomenon.
Disopyramide acts from the cytoplasmic membrane surface
To determine whether disopyramide acts from the extracellular or intracellular membrane surface, we compared the concentration-response curves following extracellular (whole-cell patch clamp technique) and cytoplasmic application (excised inside-out patches) ( Fig. 2A) . The IC 50 obtained from cytoplasmic application (IC 50 = 25 ± 4.8 μM) was four times lower than that for external application (IC 50 = 92.5 ± 9.9 μM). This result further suggests that disopyramide acts from the inside of the membrane.
Disopyramide is an open channel blocker of Kv1.5
To determine whether disopyramide is a Kv1.5 open channel blocker, we recorded Kv1.5 currents before and after a pulse-free period of incubation with 100 μM of disopyramide. Figure 2B (inset) presents superimposed Kv1.5 currents elicited at a test potential of +60 mV before and after exposure to 100 μM disopyramide for 10 min without pulsing at a holding potential of −80 mV. The initial value of the I drug /I control relationship (Fig. 2B ) was close to 1, suggesting a tonic block of <5% and the remainder of the steady-state block of 55 ± 7% developed during the pulse.
Next, we compared the effects of internal and external application of disopyramide during a depolarizing pulse. Disopyramide (100 μM) was applied for 2 s during a 10-s depolarizing pulse to +60 mV, to the external side of the membrane in the whole cell configuration (Fig. 3A) or to the intracellular side of an excised insideout patch (Fig. 3B ). When applied to the external side of the membrane, disopyramide caused a 12% reduction in current and did not reach a steady-state. When applied to the internal side of the membrane, disopyramide caused a 63% reduction in current that was complete in 215 ± 28 ms (n = 4).
Alanine-scanning mutagenesis of Kv1.5 pore residues
Sixteen residues located in the S6 domain or between the pore helix and the selectivity filter were chosen for the alanine-scan based on their proximity to the central cavity, as previously described (19, 20) . Disopyramide was applied at a concentration 1 mM and Kv1.5 current inhibition was assessed at the end of 200 ms test pulses to +60 mV. Because the P513A mutation caused a large depolarizing shift in the voltage dependence of activation (20) , block was assessed at a test potential of +80 mV for this mutant. Disopyramide (1 mM) caused an 85% reduction in WT Kv1.5 current (Fig. 4A) . The potency of disopyramide block was significantly reduced (P<0.05) by three mutant Kv1.5 channels (Ile502, Leu506, and Val512) (Fig. 4: A and B) . The IC 50 for disopyramide was determined for these mutant channels (Fig. 4C) . The V512A mutant caused a 22-fold increase in the IC 50 for disopyramide (IC 50 = 2007 ± 321 μM), while I502A and L506A increased the IC 50 sixfold (IC 50 = 545 ± 137 μM) and fivefold (IC 50 = 499 ± 119 μM), respectively (Fig. 4C) .
Discussion
The class Ia antiarrhythmic drug disopyramide is used for the maintenance of sinus rhythm in patients with AF and for the prevention of ventricular tachycardia or fibrillation (9) . In cardiac myocytes, disopyramide is known to antagonize actions of acetylcholine (ACh) inhibiting the G protein-gated potassium current (I KACh ) (21, 22) , in addition to depress directly the inward Na + currents (23, 24) . In the present work, we found that disopyramide blocked Kv1.5 channels in a similar manner to that described for quinidine (25) . Block by disopyramide exhibited several features typical of an open channel blocker. First, block mainly occurred after channel opening and increased sharply in the voltage range of channel activation. Second, slowed deactivation and tail current crossover in the presence of disopyramide was observed, suggesting that drug binding impeded closure of the activation gate. This is similar to the so-called "foot-in-the-door" mechanism first hypothesized by Armstrong (26) to describe the kinetics of unblock of squid axon K + channels by tetraethylammonium derivatives. Third, cytoplasmic application of disopyramide produced rapid block of Kv1.5 currents, while extracellular application caused slower onset and less pronounced block. Finally, the IC 50 for channel block was fourfold lower when disopyramide was applied to the cytoplasmic face of inside-out patches as compared to external application in the whole-cell configuration. Therapeutic doses of disopyramide typically result in plasma concentrations of 9 -22 μM (27); at these concentrations, the Kv1.5 current is significantly blocked (IC 50 = 25 ± 4.8 μM), suggesting a clinically relevant effect.
The disopyramide molecule has an amino group with a pK a of 10.4. At physiologic pH, more than 99.9% of the molecules are charged, which hinders the passage of drug across the cellular membrane to account for the slower rate of onset for externally applied disopyramide. Numerous studies have shown that blockers of Na + , Ca
2+
, and K + channels bind to residues within the S6 segment and/ or regions near the selectivity filter (28 -33) . For the Kv1.5 channel blockers quinidine, benzocaine, and bupivacaine, a residue at the base of the pore helix (Thr479) and residues in the S6 domain (Thr507, Leu510, and Val514) were identified as potential drugbinding sites (18, 25, 34 -37) . Interestingly, the resolved Kv1.2 structure predicts that these S6 residues point away from the central cavity (38) . Several residues have been identified within the pore helix and S6 domain of Kv1.5 as putative common drug-binding sites for a number of novel antiarrhythmic agents (19, 20, 39, 40) . Most of those residues face toward the central cavity of the channel. Unlike all the Kv1.5 channel blockers studied to date, residues at the base of the pore helix were not important molecular determinants of disopyramide block. Mutations of T479 and / or T480 significantly reduced sensitivity to AVE0118, S0100176, ICAGEN-4, S9947, and vernakalant (19, 20, 39, 40) , but did not appreciably influence disopyramide block. This observation suggests that disopyramide does not bind as deep within the central cavity to reach residues at the base of the pore helix, as reported for other Kv1.5 channel blockers. Our mutagenesis scan identified Val512 as the primary molecular determinant for disopyramide block with lesser contributions from Ile502 and Leu506. Val512 is predicted to face the central cavity of the channel pore and forms the conserved Pro-Val-Pro motif. Why does disopyramide induce a "foot-in-the-door" phenomenon, while S0100176 does not, despite sharing Val512 as an important drug-binding site? Based on molecular modeling, Decher et al. proposed that the S0100176 compound occupied a space between the base of the pore helix and the Pro-Val-Pro motif, allowing the activation gate to fully close, trapping the molecule within the pore cavity. Because disopyramide does not bind to the base of the pore helix, it might straddle the Pro-Val-Pro motif to impede channel closure.
The side chains of the two other residues identified as putative binding sites, Ile502 and Leu506, are positioned away from the central cavity (19, 20) . Mutation of these residues caused smaller shifts in IC 50 for disopyramide, compared to Val512. Interestingly, drug-affinities of AVE0118, vernakalan, and flecainide were also decreased by the I502A mutation (19, 40) . The interacting mechanism of disopyramide with these residues is not clear. However, it has been suggested that substitution of large hydrophobic residues by Ala produce a local alteration affecting the side chains orientation of the nearby residues and consequently disturbing the interactions with drugs (19) .
The observation that disopyramide interacts primarily with a single residue (Val512) may explain its low potency relative to ICAGEN-4, S9947, S0100176, and AVE0118 that interact with several residues within the central cavity. High-potency hERG blockers simultaneously interact with a number of residues located in the S6 domain and near the pore helix (33, 41) . But most of the low-potency hERG blockers like propafenone (42, 43) , erythromycin (44) , and maprotiline (45) interact with one or at most two residues located in the S6 domain and face to the internal cavity of the hERG channel.
In conclusion, we found that the antiarrhythmic drug disopyramide is a low potency open channel blocker of Kv1.5 and accesses the cavity of the pore from the cytoplasmic face of the membrane. Alanine-scanning mutagenesis of residues located in the S6 domain of Kv1.5 suggests that disopyramide interacts primarily with Val512 which faces the central cavity of the channel. However mutation of two residues predicted to face away from the central cavity (Ile502 and Leu506) decreased the apparent potency of disopyramide block. Our study highlights the importance of Val512 located in the Pro-Val-Pro gating motif for drug-binding and channel function.
